Schrödinger $SDGR
Recent IPO Schrödinger extends its existing collaboration with AstraZeneca, 
AZN, aimed at enhancing the former's Free Energy Perturbation technology for the optimization of key properties of biologics, particularly binding affinity. As technically, it is rising and needs to break the trendlines and hold above $45.
AZN, aimed at enhancing the former's Free Energy Perturbation technology for the optimization of key properties of biologics, particularly binding affinity. As technically, it is rising and needs to break the trendlines and hold above $45.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.